Read More Pharma Industry News Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation,… byPallavi MadhirajuJune 4, 2024